Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.



PRESS ROOM
03/10/10 Protalix [PLX] Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors
03/03/10 Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health
02/11/10 Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium
02/04/10 Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network
02/02/10 Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease
01/13/10 European Medicines Agency′s COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix′s taliglucerase alfa
12/09/09 Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher′s Disease
12/01/09 Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
10/29/09 Protalix BioTherapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference
10/15/09 Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO™ for the Treatment of Gaucher Disease
09/22/09 Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug
09/14/09 Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease
09/08/09 FDA Grants Protalix Orphan Drug Designation for prGCD
08/25/09 Protalix Receives FDA Fast Track Designation for prGCD
08/17/09 U.S. Food and Drug Administration Approves Protalix's Treatment Protocol for prGCD
PROTALIX BIOTHERAPEUTICS

2 Snunit St., Science Park,
POB 455, Carmiel 20100, Israel.

T:   +972-4-9028100
F:   +972-4-988-9489
E:   
      
© 2007 Protalix Biotherapeutics. All Rights Reserved.